Aura Biosciences, Inc. financial data

Symbol
AURA on Nasdaq
Location
80 Guest Street, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.74K % -4.06%
Debt-to-equity 14.1 % -9.73%
Return On Equity -41.6 % -1.81%
Return On Assets -36.4 % -3.17%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50M shares +30.6%
Common Stock, Shares, Outstanding 49.8M shares +30.3%
Entity Public Float 225M USD -19.8%
Weighted Average Number of Shares Outstanding, Basic 49.7M shares +30.1%
Weighted Average Number of Shares Outstanding, Diluted 49.7M shares +30.1%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 71.2M USD +22.6%
General and Administrative Expense 21.8M USD +10.8%
Operating Income (Loss) -93.1M USD -19.6%
Nonoperating Income (Expense) 10.1M USD +44.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -83M USD -13.4%
Income Tax Expense (Benefit) 43K USD
Net Income (Loss) Attributable to Parent -83.2M USD -17.5%
Earnings Per Share, Basic -1.74 USD/shares +10.3%
Earnings Per Share, Diluted -1.74 USD/shares +10.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 25.4M USD -54.3%
Cash, Cash Equivalents, and Short-term Investments 149M USD +33.7%
Other Assets, Current 3.42M USD +504%
Assets, Current 183M USD +19.2%
Property, Plant and Equipment, Net 3.33M USD -31.5%
Operating Lease, Right-of-Use Asset 17.7M USD -9.33%
Other Assets, Noncurrent 22K USD -96.8%
Assets 205M USD +14.2%
Accounts Payable, Current 1.99M USD +33.6%
Liabilities, Current 14.7M USD +35.1%
Operating Lease, Liability, Noncurrent 16M USD -6.97%
Liabilities 30.7M USD +9.36%
Accumulated Other Comprehensive Income (Loss), Net of Tax 607K USD
Retained Earnings (Accumulated Deficit) -348M USD -31.4%
Stockholders' Equity Attributable to Parent 175M USD +15.1%
Liabilities and Equity 205M USD +14.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -24.5M USD -49%
Net Cash Provided by (Used in) Financing Activities 253K USD +25.9%
Net Cash Provided by (Used in) Investing Activities 9.4M USD
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 49.8M shares +30.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -14.8M USD +82.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 26.2M USD -53.6%
Deferred Tax Assets, Valuation Allowance 81.9M USD +36.5%
Deferred Tax Assets, Gross 87.3M USD +32.7%
Operating Lease, Liability 19.1M USD -5.47%
Depreciation 1.17M USD -13%
Payments to Acquire Property, Plant, and Equipment 88K USD -19.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -82.5M USD -16.5%
Lessee, Operating Lease, Liability, to be Paid 28.5M USD -10.1%
Property, Plant and Equipment, Gross 9.29M USD -3.76%
Operating Lease, Liability, Current 3.13M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.41M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.31M USD +2.99%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 9.38M USD -18.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.51M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 46M USD +13.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.61M USD +2.97%
Operating Lease, Payments 751K USD -2.21%
Additional Paid in Capital 522M USD +25.3%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 11.4M USD +42.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%